Showing results (241-250 of 267) with videos related to
Sort By:
Pageof 27
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2006
Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers OvariensAndreas du Bois, Beatrice Weber, Justine Rochon, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II studyAlexander Burges, Pauline Wimberger, Carolin Kümper, et al.Molecular Immunology|September 6, 2005
MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumorsKlaus Brischwein, Bernd Schlereth, Benjamin Guller, et al.International Journal of Surgery (London, England)|February 24, 2025
Risk factors for anastomotic leakage and its impact on survival outcomes in radical multivisceral surgery for advanced ovarian cancer: an AGO-OVAR.OP3/LION exploratory analysisFabian Trillsch, Bastian Czogalla, Sven Mahner, et al.European Journal of Cancer (Oxford, England : 1990)|April 10, 2012
Mastectomy trends for early-stage breast cancer: a report from the EUSOMA multi-institutional European databaseCarlos A Garcia-Etienne, Mariano Tomatis, Joerg Heil, et al.Gynecologic Oncology|March 15, 2024
Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancerPaul Gass, Falk C Thiel, Lothar Häberle, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2006
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCGJacobus Pfisterer, Marie Plante, Ignace Vergote, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2022
Bevacizumab May Differentially Improve Prognosis of Advanced Ovarian Cancer Patients with Low Expression of VEGF-A165b, an Antiangiogenic VEGF-A Splice VariantPauline Wimberger, Mara Julia Gerber, Jacobus Pfisterer, et al.Breast Cancer Research and Treatment|October 15, 2013
Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patientsAnja Welt, Mitra Tewes, Bahriye Aktas, et al.Journal of Medical Genetics|December 4, 2020
Sensitivity and specificity of loss of heterozygosity analysis for the classification of rare germline variants in BRCA1/2: results of the observational AGO-TR1 study (NCT02222883)Jan Hauke, Philipp Harter, Corinna Ernst, et al.Pageof 27